Cantor Fitzgerald Maintains Overweight on Cabaletta Bio, Raises Price Target to $30
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Cantor Fitzgerald analyst Josh Schimmer maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and raises the price target from $15 to $30.
Cantor Fitzgerald analyst Josh Schimmer maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and raises the price target from $15 to $30.